The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

gcinternational.com

Founded Year

2009

Stage

Debt - III | Alive

Total Raised

$100M

Last Raised

$10M | 10 yrs ago

About GC International

GC International is a hub for industrial and petrochemical facilities and is a wholly-owned subsidiary of PTT Global Chemical Public Company, a petrochemical and material conglomerate headquartered in Thailand. In addition to serving as a global business development and scouting arm for new businesses, GCI also supports GC in managing several key international investments.

GC International Headquarter Location

3040 Post Oak Blvd Suite 400

Houston, Texas, 77056,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GC International

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GC International is included in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

305 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

A

Advanced Materials

1,256 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

GC International Patents

GC International has filed 19 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2013

7/27/2021

Metabolism, Dicarboxylic acids, Cellular respiration, Metabolic pathways, Biochemistry

Grant

Application Date

9/13/2013

Grant Date

7/27/2021

Title

Related Topics

Metabolism, Dicarboxylic acids, Cellular respiration, Metabolic pathways, Biochemistry

Status

Grant

Latest GC International News

Excelimmune Grabs $10.5M, Aveo Gets $15M In J&J Deal, Myriant Aims for $125M IPO, & More Boston-Area Deals News

Jun 1, 2011

XconomyBoston —  Boston tech and life sciences companies kept busy even through the holiday weekend with partnership, IPO, and financing news. — Proteostasis Therapeutics of Cambridge, MA, received an initial payment of $20 million from Elan to develop traditional small molecule drugs and diagnostics against neurodegenerative diseases like Parkinson’s, Huntington’s, and multiple sclerosis. The partnership could also include another $30 million for Proteostasis over the next five years. —Nashua, NH-based AutoVirt, a maker of file virtualization software, took in $5 million in equity financing from five investors , an SEC filing showed. —Woburn, MA-based Excelimmune, which develops drugs made with human recombinant polyclonal antibodies, said it pinned down a $10.5 million Series B funding round, from both new and existing individual backers . The biotech said the money will go to enhancing its discovery platform and manufacturing processes, as well as advancing development of its treatment for methicillin-resistant staph infections, Staphguard. —Aveo Pharmaceuticals (NASDAQ: AVEO ) of Cambridge said that it had entered into a licensing deal with Centocor Ortho Biotech, a unit of Johnson & Johnson (NYSE: JNJ ), taking in $15 million upfront and potentially $540 million more in milestone payments and royalties. The companies will work together on Aveo’s antibodies targeting a receptor that may be involved in the regulation of tumor growth, cancer survival and metastasis, and bone disruption. — Novophage, a Boston-based startup engineering viruses (phages) to combat bacterial contamination in industries like oil and gas, paper, and heating and cooling systems, drank up $5.7 million in Series A financing . The deal was led by Flybridge Capital Partners, and also included Founder Collective, Boston University, and strategic investors Chevron Technology Ventures and The Kraft Group. — Quincy, MA-based biochemical developer Myriant Technologies plans to raise $125 million in an initial public offering , an SEC filing revealed. The company reported a $16 million loss on $14 million in revenue in 2010, and is looking for the IPO proceeds to fund the completion of its plant in Louisiana, as well as working capital, research and development, and general corporate purposes.

GC International Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GC International Rank

  • When was GC International founded?

    GC International was founded in 2009.

  • Where is GC International's headquarters?

    GC International's headquarters is located at 3040 Post Oak Blvd, Houston.

  • What is GC International's latest funding round?

    GC International's latest funding round is Debt - III.

  • How much did GC International raise?

    GC International raised a total of $100M.

  • Who are the investors of GC International?

    Investors of GC International include U.S. Department of Agriculture and PTT Public Chemical Company.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.